Skip to content

Advertisement

Open Peer Review Reports for: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Back to article

Pre-publication versions of this article are available by contacting editorial@trialsjournal.com.

Original Submission
19 Jan 2017 Submitted Original manuscript
14 Jun 2017 Reviewed Reviewer Report - Joel Dubin
29 Jun 2017 Author responded Author comments - Jamie Oughton
Resubmission - Version 2
29 Jun 2017 Submitted Manuscript version 2
14 Jul 2017 Reviewed Reviewer Report - Joel Dubin
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
14 Jul 2017 Editorially accepted
26 Jul 2017 Article published 10.1186/s13063-017-2107-0

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement